Briefing: FY AIDS Research, $20M Appropriation

DISTRIBUTION OF FY95 FUNDS
RETROVIROLOGY PROGRAM.l. AL
PROGRAM AREA POM ONLY APPROPRIATION
(POM Wrr PLUS-UP)
(K) (K)
A. Vaccines for Prevention
1. Vaccine Construct Development 1,600 5,400
2. Vaccine Trial Development 3,600 6,800
3. Defining.Protective Immunity 1,000 4,000
4. Vaccine Modeling 0 1,600
SUBTOTAL 5,300 17.800
B. Behavioral Prevention
1. High Risk Cohort Development 0 1,600
2. Minority Initiatives 0 1,300
3. Interactive Videodisc 0 400
4. Preventing Transmission 0 1,200
SUBTOTAL 0 4,500
C. Disease Prevention/Virology
1I. HIV Antiviral Program 0 1,900
2. Surrogate Markers 0 2,200
3. Gene Transfer Product 0 4,200
4. Tissue Viral Burden 0 1,500
SUBTOTAL 0 9.800
D. Vaccine Therapy
1. gpl60 Vaccine Trial 5,900 5,900
2. Immune Response Quantitation 0 1,900
3. Immune Product Development 0 1,700
4. Stabilizing Adjuvants 700 700. 5. Induction of Mucosal Immunity 0 400
SUBTOTAL 6,600 10,600
E. Intervention Assessment
1. Tri-Service Repository 1,200 3,700
2. Viral Quantitative Assays 0 500
3. Cellular Immune Assay 0 500

+a

20
N

SUBTOTAL

1,200
14,000

4,700
47,400

TOTAL